Published in Pharma Law Weekly, January 10th, 2006
"Galectin-3 and MUC2 intestinal mucin each have been correlated with the malignant behavior of colon cancer cells. Galectin-3 modulates expression of MUC2 protein, but the specific regulatory mechanisms are unknown," wrote S.M. Song and colleagues, M.D. Anderson Cancer Center.
"This study sought to determine how galectin-3 increases MUC2 expression. Galectin-3 levels in human colon cancer cells of high and low metastatic ability were manipulated via expression of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.